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Lymphatic vessels arise during development through
sprouting of precursor cells from veins, which is
regulated by known signaling and transcriptional
mechanisms. The ongoing elaboration of vessels to
form a network is less well understood. This involves
cell polarization, coordinated migration, adhesion,
mixing, regression, and shape rearrangements. We
identified a zebrafish mutant, lymphatic and cardiac
defects 1 (lyc1), with reduced lymphatic vessel devel-
opment. A mutation in polycystic kidney disease 1a
was responsible for the phenotype. PKD1 is the
most frequently mutated gene in autosomal domi-
nant polycystic kidney disease (ADPKD). Initial
lymphatic precursor sprouting is normal in lyc1
mutants, but ongoing migration fails. Loss of Pkd1
in mice has no effect on precursor sprouting but
leads to failed morphogenesis of the subcutaneous
lymphatic network. Individual lymphatic endothelial
cells display defective polarity, elongation, and
adherens junctions. This work identifies a highly
selective and unexpected role for Pkd1 in lymphatic
vessel morphogenesis during development.
INTRODUCTION
The lymphatic vasculature forms in the embryo as a result of
specification of lymphatic endothelial cell (LEC) fate, followed
by coordinated sprouting, morphogenesis, and network elabo-
ration. LEC fate is specified through key transcription factors,
which act in embryonic veins (Franc¸ois et al., 2008; Srinivasan
et al., 2010; Wigle and Oliver, 1999). LEC precursors subse-
quently sprout from veins and migrate through the embryo
(reviewed in Koltowska et al., 2013). This process is under the
control of VEGFC/VEGFR3 signaling (Karkkainen et al., 2004)and its modulators (reviewed in Koltowska et al., 2013). In
mouse, lymphatic precursors form lymph sacs in the anterior
of the embryo (Franc¸ois et al., 2012; Yang et al., 2012), which
likely remodel into major lymphatic vessels (Ha¨gerling et al.,
2013). Superficial LECs (sLECs) migrate dorsally as loosely
attached individual cells to form the subcutaneous lymphatic
network (Ha¨gerling et al., 2013). Although several guidance mol-
ecules, cellular interactions, and extrinsic forces pattern embry-
onic lymphangiogenesis (reviewed in Koltowska et al., 2013),
much remains to be understood about the cellular mechanisms
that regulate LEC polarization, adhesion, outgrowth, remodeling,
and morphogenesis.
In zebrafish, there are strong parallels with mammals in the
processes that regulate lymphatic vascular development (Hogan
et al., 2009b; Ku¨chler et al., 2006; Yaniv et al., 2006). We have
used forward genetic screens to identify zebrafish mutants that
lack lymphatic vessels. Here, one zebrafish mutant uncovers a
surprising role for the ADPKD gene Pkd1 in lymphatic vascular
development. We show that this function of Pkd1 is conserved
and cell autonomous in endothelial knockout mice. Our findings
suggest a uniquely staged role for PKD1 in the regulation of
lymphatic vascular morphogenesis.
RESULTS
lyc1 Mutants Fail to Form a Lymphatic Vasculature
We identified a zebrafish mutant dubbed lymphatic and cardiac
defects 1 (lyc1). lyc1mutants exhibited a reduction or loss of the
main axial lymphatic vessel, the thoracic duct (TD) at 4 days post-
fertilization (dpf) as well as mild cardiac edema, while retaining
blood circulation (Figures 1A–1D and 1I). By 5 dpf, mutant blood
flow was reduced and cardiac edema increased in severity (Fig-
ure S1; data not shown). To determine the origins of the pheno-
type,weexaminedgeneexpression for arteriovenousgenes, lym-
phangiogenesis regulators (includingchemokinesand receptors),
and flow-induced pathways at 32 hr postfertilization (hpf), during
the initiation of lymphatic development. These markers were un-
changed in lyc1 embryos (Figure S1). In the zebrafish, precursorCell Reports 7, 623–633, May 8, 2014 ª2014 The Authors 623
Figure 1. lyc1 Mutants Display Reduced Lymphatic Development
(A and B) Overall morphology of wild-type siblings (A) and lyc1 mutants (B) at 4 dpf.
(C and D) The vasculature Tg(fli1a:EGFPy1; flt1:tomatohu5333Tg) of (C) wild-type (WT) (arrowheads indicate thoracic duct) and (D) lyc1 mutants at 4 dpf (asterisks
indicate absence of thoracic duct).
(E and G) The vasculature Tg(fli1a:EGFP y1; flt1:tomatohu5333Tg) in wild-type sibling (E) and mutant embryos (G) at 56 hpf (arrows indicate lymphatic precursors
known as parachordal lymphangioblasts, PLs).
(F and H) flt1:tomatohu5333Tg expression marks the arterial ECs, a loss of signal (brackets) indicating venous intersegmental vessels (vISVs).
(I–K) Quantification of (I) thoracic duct extent across ten somites (WT n = 40, lyc1 n = 17), (J) parachordal lymphangioblasts (WT n = 78, lyc1 n = 17), and (K) venous
sprouts (WT n = 40, lyc1 n = 15). DA, dorsal aorta; PCV, posterior cardinal vein.
Error bars indicate SEM. See also Figures S1 and S2.
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Figure 2. lyc1 Is a pkd1a Mutant
(A) Overview of positional cloning of lyc1. Individual recombinant embryos (labeled in red left [from 776 embryos analyzed], labeled in blue right [from 314 embryos
analyzed]) identify flanking polymorphic markers and limit the critical interval to a region containing partial sequences for pkd1a and tsc2.
(B) Sequence chromatograms showing the wild-type (upper) and pkd1a mutant (R3607X, lower) sequences.
(C) Overall morphology of 5 dpf WT, lyc1, MO-pkd1b, lyc1/MO-pkd1b, and MO-pkd2 embryos. The injection of MO-pkd1b into lyc1 mutants recapitulates the
published MO-pkd1a/1b double loss-of-function phenotype (Mangos et al., 2010).
(D) Expression pattern of pkd1a by in situ hybridization in the trunk of wild-type zebrafish at 24 hpf and 32 hpf.
(E) Quantitative RT-PCR for markers enriched in venous endothelial cells (VECs); kdrl, cdh5, LECs; prox1a, nfatc1, nrp2a; and both flt4 and lyve1 demonstrated
the purity of FACS-isolated populations at 5 dpf.
(F) Quantitative RT-PCR for pkd1a, pkd1b, and pkd2 transcripts in 3, 5, and 7 dpf VEC and LEC populations.
(G–I) The vasculature of 5 dpf WT, lyc1/MO-pkd1b and MO-pkd2 embryos (5 and 7.5 ng MO, respectively); asterisk indicates absence of thoracic duct in
Tg(fli1a:EGFP y1; kdrl:egfps843) embryos.
Error bars indicate SEM. See also Figures S3 and S4.LECs emerge from the posterior cardinal vein (PCV) during
secondary angiogenesis and migrate dorsally to the horizontal
myoseptum to form parachordal lymphangioblasts (PLs).
Concomitantly, venous sprouts form intersegmental veins
(vISVs). Strikingly, the numbers of vISVs and PLs were normal in
lyc1mutants (Figures 1E–1H, 1J, and 1K).
This phenotype differs from described mutants for vegfc,
vegfr3, or ccbe1 (Hogan et al., 2009a, 2009b; Le Guen et al.,
2014; Villefranc et al., 2013), which lack all venous sprouting.
Time-lapse imaging showed that the lymphatic defect resulted
from a block in themigration of PLs out of the horizontal myosep-
tum (Movies S1 and S2). Quantitative analysis of cell behavior
spanning this period of altered migration revealed that mutant
precursor LECs remain mobile but show altered exploratory
behavior and filopodial extension dynamics, consistent with
impaired directional migration (Movies S3 and S4; Figure S2).
A Loss-of-Function Mutation in pkd1a Is Responsible for
the lyc1 Phenotype
Meiotic mapping (see the Experimental Procedures) was used to
identify a region of chromosome 1 containing the lyc1 locus. The
critical interval (Figure 2A) contained two genes, tuberous
sclerosis 2 (tsc2) and polycystic kidney disease Ia (pkd1a). In
the zebrafish genome, pkd1 (encoding Polycystin1) is presentas duplicate genes, with pkd1a coding for a conserved 4281
amino acid protein. Sequencing revealed a mutation in pkd1a,
introducing a premature stop codon (R3607X) (Figure 2B). This
mutation was predicted to result in the failed translation of six
of the 11 transmembrane domains and essential C-terminal
cytoplasmic tail of the protein.
In humans,PKD1 and PKD2 (encoding POLYCYSTIN2) are the
most commonly mutated genes in ADPKD (for review, see
Chapin and Caplan, 2010; Zhou, 2009). PKD1 haploinsufficiency
and loss of function have also been frequently associated
with cardiovascular complications (reviewed in Rossetti and
Harris, 2013). In mammals, POLYCYSTIN1 protein localizes to
primary cilia, apical membranes, adherens, and desmosomal
junctions. It can act as a mechanosensory signaling protein,
transducing extracellular signals through its cytoplasmic C-ter-
minal domain (reviewed in Zhou, 2009). POLYCYSTIN1 binds
to POLYCYSTIN2 (a calcium pump) at the membrane to regulate
Ca2+ influx and signaling but also binds to E-cadherin, b-catenin,
and components/effectors of the planar cell polarity pathway
(Castelli et al., 2013; Lal et al., 2008; Roitbak et al., 2004).
Previous studies depleting Polycystin1 (a and b) in zebrafish
found that MO-pkd1a/b embryos exhibit a specific body curva-
ture phenotype (Mangos et al., 2010). We injected MO-pkd1b
into our pkd1a mutant embryos and robustly induced thisCell Reports 7, 623–633, May 8, 2014 ª2014 The Authors 625
Figure 3. Pkd1 Cell-Autonomously Regulates Subcutaneous Lymphatic Vascular Development in Mice
(A–C) Morphology of WT, Pkd1KO, and Pkd1iDECKO embryos at 14.5 dpc (arrowhead indicates edema).
(D–F) Lymph sacs (LS) in WT, Pkd1KO, and Pkd1iDECKO embryos stained with endomucin, LYVE1, and PROX1. JV, jugular vein. Scale bar represents 100 mm.
(G–I) Hematoxylin and eosin staining in WT, Pkd1KO, Pkd1iDECKO embryos at 14.5 dpc. Lymph sacs (LS) indicated.
(J and K) Subcutaneous lymphatics in Sox18:GFP-Cre-ERT2, Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J costained with NRP2 and PROX1 (n = 663/1,138 scored
LECs were tdTOMATO positive (58.2%), from n = 2 embryos, 13.5 dpc).
(L–N) Subcutaneous lymphatic vasculature inWT, Pkd1KO, and Pkd1DECKOmutants at 14.5 dpc. Dashed line indicated the dorsal midline of the embryo. Scale bar
represents 400 mm.
(O–Q) Representative subcutaneous lymphatic sprout in WT, Pkd1KO, and Pkd1iDECKO mutants at 14.5 dpc.
(R and S) Quantification of branchpoints/area (2,0003 1,500 mm area on both sides of the midline) in (R) WT (n = 7 embryos) and Pkd1KO (n = 7 embryos) and (S)
WT (n = 8 embryos) and Pkd1iDECKO (n = 6 embryos) embryos at 14.5 dpc.
(legend continued on next page)
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phenotype, confirming that the lyc1 mutation is a loss-of-func-
tion allele (Figures 2C and S3). Pkd1 and Pkd2 can modulate
extracellular matrix (ECM) formation (Mangos et al., 2010).
Importantly, even the most phenotypically penetrant pkd1a
mutants for lymphangiogenesis do not display the body curva-
ture associated with altered ECM.We examined several markers
and knockdown scenarios but found no evidence for increased
ECM or a role of altered matrix in the lyc1 lymphatic phenotype
(Figure S4).
pkd1a Is Expressed in Migrating LECs and Loss of
Function in the ADPKD Complex Mimics lyc1 Defects
We found that pkd1a expression was ubiquitous in the 24 hpf
embryo but was enriched in the trunk during secondary angio-
genesis at 32 hpf (Figure 2D). We saw no evidence for
nonsense-mediated decay in mutants using in situ hybridization
at 32 hpf (n = 130 embryos from a carrier incross analyzed; data
not shown). As in situ hybridization has proved insensitive in
LECs in older zebrafish (post 3 dpf), we isolated LECs using fluo-
rescence-activated cell sorting (FACS). Taking advantage of a
new transgenic line Tg(lyve1:DsRed2)nz101 (Okuda et al., 2012)
labeling embryonic veins and lymphatic vessels, crossed onto
the Tg(kdrl:egfp)s843 line (restricted to blood vessels; Jin et al.,
2005), we isolated LECs and venous ECs (VECs). We performed
quantitative PCR (qPCR) for knownmarkers, validating the spec-
ificity of cell populations (Figures 2E and S3). Consistent with the
timing of the lyc1 phenotype, pkd1a and pkd2were expressed in
VECs and LECs, with pkd1a in both populations at 3 dpf but
reduced in LECs at 5 dpf. pkd1b was expressed at low, almost
undetectable levels at all stages (Figures 2F and S3).
In endothelial cells, Polycystin1 can regulate calcium signaling
through Polycystin2 activity (Chapin and Caplan, 2010; Nauli
et al., 2003). To investigate this potential mechanism, we
knocked down Pkd2. Embryos depleted for Pkd2 exhibited a
phenotype similar to that of lyc1/MO-pkd1b embryos and
reduced TD extent (Figures 2G–2I and S3). We next treated
embryos with previously validated Ca2+ signaling antagonist
and agonists (North et al., 2009). These treatments generated
phenotypes highly reminiscent of the lyc1 phenotype (Figure S3).
Cacna1s, an L-type calcium channel targeted by the antagonist
Nifedipine, was expressed in ECs (Figure S3). Taken together,
these observations are consistent with Pkd1 functioning in the
canonical ADPKD complex.
Pkd1 Cell-Autonomously Regulates Development of the
Subcutaneous Lymphatic Vascular Network in Mice
Although most previous studies in mammalian models focus on
the role of Pkd1 in epithelia, Pkd1-null mice have been shown to
exhibit cardiovascular, skeletal, and renal defects (Boulter et al.,
2001; Kim et al., 2000; Piontek et al., 2004). Embryos devoid of
Pkd1 die after 15.5 days post coitum (dpc) displaying severe(T) Quantification of the average width of lymphatic vessels (mm) across the whol
embryos) embryos. The average is shown of n = 773, n = 354, and n = 250 measu
midline at 14.5 dpc.
(U) Quantification of nuclei/100 mm of vessel in WT (n = 12 embryos), Pkd1KO (n =
vessels counted per embryo) at 14.5 dpc.
Error bars indicate SEM. See also Figures S5 and S6.hemorrhaging and subcutaneous edema (Kim et al., 2000;
Muto et al., 2002), but a role for this gene in lymphangiogenesis
has yet to be reported.
We generated Pkd1 knockout embryos and examined their
overall morphology. We observed the previously described sub-
cutaneous edema, but not hemorrhaging (Figures 3A–3C).
Embryonic lymph sacs were present but were blood filled in
Pkd1 KO embryos (Figures 3D–3I). This phenotype suggests
that lymphatics in this mutant would not sustain fluid drainage
and may explain the subcutaneous edema. Interestingly, we
did not find any defect in lymphovenous valves at 14.5 dpc (Fig-
ure S5) perhaps suggesting that blood enters the mutant lymph
sacs early during morphogenesis, before valve maturation
(Franc¸ois et al., 2012). We next examined the developing subcu-
taneous lymphatic vasculature in dorsal embryonic skin, a useful
system to quantify lymphatic vascular phenotypes (James et al.,
2013; Kartopawiro et al., 2014). We found that Pkd1 KO embryos
exhibit defects in the morphogenesis of the lymphatic network,
with increased width of sprouting vessels, increased cell number
per vessel, and a significant reduction in network branching (Fig-
ures 3L, 3M, 3R, 3T, and 3U).
Previous studies reported that Tie2:Cre-mediated deletion of
Pkd1 did not lead to vascular abnormalities, and these knockout
mice did not display the edema observed in full knockout ani-
mals (Garcia-Gonzalez et al., 2010; Hassane et al., 2011). This
implies that the phenotypes that we observed may not reflect
endothelial autonomous function. To investigate this further,
we crossed the Tie2:Cre strain into a ROSA26r-LacZ back-
ground and examined Cre activity. Although active in blood ves-
sels, we could not detect activity throughout subcutaneous
lymphatic vessels (Figure S6). Hence, previous work would
not have uncovered function in these vessels. We generated
Tie2:Cre-mediated knockout embryos for Pkd1 and found no
subcutaneous lymphatic phenotype (Figure S5). Therefore, we
utilized Sox18:GFP-Cre-ErT2(GCE) as an additional endothelial
CRE strain (Kartopawiro et al., 2014). We validated the use of
Sox18:GCE on a Rosa26r-LacZ background, which demon-
strated activity throughout the vasculature (Figure S6). We also
used an inducible tdTomato reporter to quantify activity in sub-
cutaneous lymphatics by costaining with LEC markers NRP2
and PROX1. We found that induced Sox18:GCE was active in
58%of sprouting subcutaneous LECs at 13.5 dpc and frequently
in clonal regions spanning whole vessels (Figures 3J, 3K, and
S6H–S6Q; Movie S5).
We generated induced Pkd1 endothelial cell knockout
(iDECKO) embryos using this line. Pkd1iDECKO embryos dis-
played either mild or no subcutaneous edema at 14.5 dpc (Fig-
ure 3C), with lymph sacs present but not containing blood
(Figures 3I and 3F). In the subcutaneous lymphatic vasculature,
Pkd1iDECKO embryos displayed similar dramatic defects to germ-
line KO animals, if marginally milder on quantification (Figurese skin in WT (n = 15 embryos), Pkd1KO (n = 7 embryos), and Pkd1iDECKO (n = 6
rements, respectively, across leading lymphatic vessels from both sides of the
3 embryos), and Pkd1iDECKO (n = 6 embryos) (n = 5 representative leading edge
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3N, 3Q, 3T, and 3U).We examined the blood vasculature of Pkd1
KO embryos. Although we saw defects in Pkd1KO embryos,
these were at the dorsal midline associated with edema and
considered secondary to altered tissue architecture (Figure S5).
In contrast, Pkd1iDECKO embryos displayed normal blood vascu-
lature, including normal vessel width and branching (Figure S5).
Interestingly, Pkd1iDECKO embryos did not show reduced LEC
migration toward the midline (Figure 3N). This would be ex-
pected for mutants in known pathways such as VEGFC/
VEGFR3.
PKD1 Regulates Sprouting and Cell-Cell Junctions
In Vitro in Human LECs
Next, we examined the sprouting of human LECs in vitro in
response to VEGFC using a spheroid outgrowth assay. Small
interfering RNA (siRNA)-mediated knockdown of PKD1 in LECs
resulted in a reduced number of cells within individual spheroid
sprouts, with extensions exhibiting reduced length and abnormal
morphology (Figures 4A–4H; Figure S7). The efficacy of knock-
down with the siRNA mix was validated by qPCR, and the spec-
ificity was verified with an independent small hairpin RNA
(shRNA) knockdown (Figure S7). We examined the phenotype
of LECs in cultured monolayers and observed a rapid change
in morphology following PKD1 knockdown (Figures 4I–4P).
Stress fibers were disorganized in these cells (Figures 4I and
4M), and analysis of cell junctions revealed reduced VE-cadherin
and b-catenin and disorganized junctions following knockdown
(Figures 4J, 4K, 4N, and 4O). ZO-1 localization at tight junctions
was relatively unaffected in these assays, despite altered cell
morphology, suggesting a level of selectivity to adherens junc-
tions (Figures 4L and 4P). The levels of VE-cadherin were not
altered by western blot although b-catenin showed amild reduc-
tion (Figure S7), probably indicative of destabilized junctional
complexes.
Pkd1 Regulates Polarity and Cell-Cell Junctions during
Lymphatic Vessel Morphogenesis in Mice
Pkd1 has been implicated in the regulation of polarity in epithe-
lial cells and shown to regulate cellular convergent extension
and polarity during kidney tubule morphogenesis through
planar cell polarity (PCP) signaling (Castelli et al., 2013). PKD1
binds to PAR3 and aPKC as well as E-cadherin and b-catenin
therefore being associated with both polarity and junctional
components (Castelli et al., 2013; Lal et al., 2008; Roitbak
et al., 2004). Recently, the PCP pathway has been shown to
regulate junctional rearrangements in developing LECs, at least
during valve morphogenesis (Tatin et al., 2013).
We examined cell polarity in sprouting embryonic lymphatic
vessels. The Golgi apparatus orients toward the migration front
relative to the nucleus in many cell types including LECs (Fig-
ures 5A and 5C), serving as an ideal readout for polarity. We
quantified Golgi orientation in Pkd1 KO embryos and found it
to be significantly randomized in 14.5 dpc lymphatic vessels
compared with siblings (Figures 5A–5D and 5G). Furthermore,
this loss of polarity was associated with increased nucleus
sphericity in mutant vessels, a previously described proxy for
polarity and migratory behavior (Ha¨gerling et al., 2013)
(Figure 5H).628 Cell Reports 7, 623–633, May 8, 2014 ª2014 The AuthorsTo determine the earliest defect, we performed detailed
phenotypic analysis at 10.5 and 11.5 dpc. At 10.5 dpc, analysis
of PROX1 expression indicated that cell migration from the cardi-
nal vein and nuclear morphology was normal in mutants (Figures
5I, S6G, and S6H). However, at 11.5 dpc, although the blood
vasculature was grossly normal (Figure S5), mutant LECs at the
sprouting vessel front displayed increased nucleus sphericity
(decreased elipticity) compared with wild-type (Figure 5J). We
assessedGolgi orientation at these stages, but the direction of in-
dividual cell migration events was not regular, and the midline
cannot be used as a direction of migration until later in develop-
ment (data not shown). These early leading vessels also exhibited
increased width and numbers of nuclei relative to vessel length
similar to later Pkd1KO vessels (Figures S5I–S5J).
Finally, we investigated cell shape and the morphology of
junctions within lymphatic vessels. At 14.5 dpc, VE-cadherin
highlighted cell shape and showed that mutant cells failed to
elongate along the plane of migration toward the midline
compared with wild-type vessels (Figures 5K, 5L, 5O, 5P, and
5S). At the level of individual junctional morphology, both VE-
cadherin and b-catenin expression identified junctions that
displayed immature morphology with irregular intracellular pro-
trusions (arrowheads in Figures 5M, 5N, 5Q, and 5R). These
phenotypes were only seen in phenotypically mutant vessels
and not morphologically wild-type mutant vessels (data not
shown; phenotypic variability shown in Figure 3). Quantification
of the number of cells displaying immature junctions showed a
significant phenotype from as early as 12.5 dpc (Figures 5T–5V).
DISCUSSION
Our results, along with those of Outeda et al. (2014) published
in this issue of Cell Reports demonstrate the surprising finding
that Pkd1 is a regulator of lymphatic vessel development. In
zebrafish, at the cellular level, Pkd1 regulates LEC migration
out of the horizontal myoseptum but not initial sprouting from
veins that is regulated by ccbe1/vegfc/vegfr3 (Hogan et al.,
2009a, 2009b; Le Guen et al., 2014; Villefranc et al., 2013).
pkd1a is expressed in lymphatic precursor cells when they are
actively migrating, consistent with the earliest cellular defects
in the mutant.
It was important, given the highly studied nature of Pkd1, to ask
if this function was conserved in mammals. In knockout mice,
early specification and initial sprouting of LECs occurs normally.
However, defects are seen in the morphology of migrating LECs
at 11.5 dpc with morphological defects in the subcutaneous
lymphatic network prominent by 14.5 dpc. This uniquely timed
requirement is distinct fromphenotypes in knownpathways, sug-
gesting that Pkd1 may act by an uncharacterized mechanism in
LECs. Interestingly, the lymph sacs were blood filled in full
knockout but not in endothelial knockout mice, which displayed
only mild edema. This may be due to the staging of tamoxifen
treatment to knockout Pkd1 function from 9.5 or 11.5 dpc,
when lymph sacs are already establishing (Ha¨gerling et al.,
2013). The observation that the lymphatic phenotype was
reproduced by deletion with Sox18:GCE, active in LECs, but not
Tie2:Cre, which we observed acts in BECs, suggests that Pkd1
functions in the LECs themselves during vessel morphogenesis.
Figure 4. PKD1 Regulates Sprouting and Cell-Cell Junctions in LECs In Vitro
(A–F) Morphology of human LEC spheroids treated with control and PKD1 siRNA (50 nM) in BSA or VEGFC-supplemented conditions, stained with F-ACTIN
(green) and DAPI (blue). Scale bar represents 100 mm in (A), (B), (D), and (E) and 30 mm in (C) and (F).
(G and H) Quantification of number of sprouts (G) and number of nuclei per 100 mm of sprouts (H) in spheroids treated with control or PKD1 siRNA in BSA or
VEGFC-supplemented conditions.
(I–P) Morphology of human LECs treated with control or PKD1 siRNA (50 nM) VEGFC-supplemented conditions, stained with DAPI (blue) and F-ACTIN (green)
(I and M), b-catenin (pink) (J and N), VE-cadherin (red) (K and O), or ZO-1 (L and P).
Error bars indicate SEM. See also Figure S7.Given the diverse functions of the protein, several hypotheses
could explain the observed migration and morphogenesis de-
fects. PKD1 has been previously reported to function at the pri-
mary cilium in endothelial cells (Nauli et al., 2008). However, we
found lymphatic vessels developed normally in a ciliogenesis
mutant (ift88; Huang and Schier, 2009), we saw no evidence
for altered ciliogenesis in lyc1 mutants, and overexpression ofa Pkd1a-YFP fusion protein, driven by the pkd1a promoter
(BAC clone), did not lead to cilium enrichment (Figure S8).
Hence, we find no supportive evidence that Pkd1 in zebrafish
lymphatic development functions at the cilium. Because Pkd1
can also localize to adherens junctions, desmosomal junctions,
and intracellular organelles and has a number of binding part-
ners, it has the potential to act at diverse locations.Cell Reports 7, 623–633, May 8, 2014 ª2014 The Authors 629
Figure 5. Pkd1 Regulates Polarity and Cell-Cell Junctions in Mouse Embryonic Lymphatic Vessels
(A and B) Subcutaneous lymphatic vessels in skin of WT and Pkd1KO embryos at 14.5 dpc, stained with endomucin, NRP2, PROX1, and GOLPH4 (Golgi
apparatus), non-LEC GOLPH4 staining subtracted. Scale bar represents 20 mm.
(C and D) PROX1, GOLPH4 staining in WT and Pkd1KO lymphatic vessels. Arrowhead indicates Golgi; N, nucleus.
(legend continued on next page)
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The earliest consequences of loss of function are changes
in cell morphology during morphogenesis, including altered
polarity and adhesion. Cell polarity and adhesion are intimately
associated and must be carefully regulated to control tissue
morphogenesis. It is hard to determine which defect is pri-
marily regulated by Pkd1. However, parallels can be drawn
with recent findings in kidney tubule development where Pkd1
regulates cellular convergent extension during tube formation
through the PCP pathway (Castelli et al., 2013). Although it will
take further work to delineate the pathways modulated by
Pkd1 in LECs, the finding of a crucial role in lymphatic vascular
development is unexpected and serves as a unique entry point
to understand lymphatic vascular morphogenesis.
EXPERIMENTAL PROCEDURES
Zebrafish Strains, Mapping, and Genotyping
Animal use conformed to guidelines of the animal ethics committee at the
University of Queensland. Zebrafish were maintained and screening per-
formed as previously described (Hogan et al., 2009a). Mapping and genotyp-
ing was performed as previously described (Hogan et al., 2009a). Primers are
given in Supplemental Experimental Procedures. The lyc1 mutant allele is
formally designated pkd1ahu5855. The Tg(flt1:YFP)hu4624Tg, Tg(kdrl:egfp)s843,
Tg(fli1a:EGFP)y1, Tg(6.5kdrl:mcherry)s916, Tg(0.8flt1:tdTomato)hu5333Tg,
and Tg(lyve1:DsRed2)nz101 lines were previously described (Bussmann et al.,
2010; Hogan et al., 2009b; Jin et al., 2005; Krueger et al., 2011; Lawson and
Weinstein, 2002; Okuda et al., 2012).
Mouse Strains
We generated Sox18:GFP-Cre-ErT2(GCE), B6.129S4-Pkd1tm2Ggg/J (Pkd1f/f);
Rosa26rLacZ (C57BL/6 background) mice by crossing Pkd1f/f mice to both
Rosa26rLacZ and Sox18:GFP-Cre-ErT2 mice and breeding resulting carriers.
We generated Tie2:Cre, Rosa26rLacZ (C57BL/6 background) mice by crossing
Tie2:Cre mice to Rosa26rLacZ and breeding resulting carriers. We generated
Sox18:GFP-Cre-ErT2(GCE), Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J by cross-
ing Sox18:GFP-Cre-ErT2 mice to Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J
homozygous mice. We generated Pkd1/ embryos by crossing Pkd1f/f mice
to B6.C-Tg(CMV-cre)1Cgn/J and incrossing resulting progeny in subsequent
generations. Genotyping primers are described in Supplemental Experimental
Procedures.(E and F) Lateral view of (E) WT (n = 3) and (F) Pkd1KO (n = 2) bisected embryo
morphology of migrating sLEC nuclei (analyzed above dashed line). Scale bar re
(G and H) Quantification of nucleus-Golgi vector angle (G) in WT (n = 3 embryos, n
sphericity (width to length ratio) in WT (n = 7, n = 299 nuclei) and Pkd1KO (n = 7,
(I and J) Quantification of nucleus sphericity in (I) dorsal-most iLECs in WT (n = 5
sLECs in WT (n = 3, n = 131 nucleus) and Pkd1KO (n = 2, n = 93 nucleus) embryo
(K and O) Representative subcutaneous lymphatic vessels in (K) WT and (O) Pkd
Scale bar represents 20 mm
(L and P) Representative cell shape schematics based on vessels shown in (K) a
sided arrows indicate elongation axes.
(M and Q) WT and Pkd1KO mutant cells at 14.5 dpc stained with PROX1 and V
represents 5 mm.
(N and R) WT and Pkd1KO mutant cells at 14.5 dpc stained with PROX1 and
represents 5 mm.
(S) Quantification of the angle of cell elongation relative to the direction of mig
embryos).
(T) Quantification of the average number of cells with abnormal junctions (stained
(n = 4 embryos, n = 16 vessels) at 14.5 dpc.
(U) Quantification of abnormal junctions (stained with b-catenin) in WT (n = 3 em
(V) Quantification of the average number of cells with abnormal junctions (stained
(n = 3 embryos, n = 7 vessels) at 12.5 dpc.
iLECS, initial LECs; PLLV, peripheral longitudinal lymphatic vessel; sLECS, supeImaging and Analysis
For confocal and spinning disk imaging, embryos were mounted as previously
described (Hogan et al., 2009b). Imaging was performed on a LSM Zeiss
510 NLO, META, or Zeiss 710 FCS confocal microscope with a 103, 203,
and 403 dry objective and 633 oil objective. Images were analyzed with the
Zen software, Biplane IMARIS, Photoshop, and ImageJ.
Morpholino Oligomers
Morpholino oligomers against pkd1a (morpholino oligomer [MO] ex8), pkd1b
(MO ex45), and pkd2 (MO ATG) were described in Mangos et al. (2010) and
were injected at 5, 7.5, or 10 ng/embryo as described (Hogan et al., 2008).
Quantitative Real-Time PCR
Procedures were performed in order to comply with MIQE guidelines (Bustin
et al., 2009) and are given in full in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, one table, and five movies and can be found with this article
online at http://dx.doi.org/10.1016/j.celrep.2014.03.063.
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 SUPPLEMENTAL EXPERIMENTAL PROCEDURES. Related to main experimental procedures. 
 
Additional animal procedures 
For the induction of Cre-mediated recombination in embryos, 1.5 mg tamoxifen suspension in sunflower 
oil were injected intra-peritoneally into pregnant females at 9.5, 10.5 and 11.5 or 11.5, 12.5, 13.5 dpc in 
two separate regimes. 
 
GOLPH4 processing  - subtraction of background Golgi staining 
The nucleus-Golgi angle relative to the dorsal midline was measured by first using the NRP2 expressing 
tissues as a mask to remove non-endothelial GOLPH4 staining during processing. The angle was 
subsequently measured between the perpendicular to the midline and the nucleus-Golgi orientation 
vectors in endothelial cells. Sphericity was measured in nuclei located within 150 µm of the leading 
edge, on both side of the midline in 14.5 dpc embryos. At earlier stages (10.5 and 11.5dpc), polarity and 
nuclear sphericity were assessed in cells at the lymphatic vascular migratory front only.   
 
Statistical analysis  
We used a Mann-Whitney rank sum t-test using Prism (GraphPad software), for all figures except in 
Figure 2 (E), Figure 4 (G-H) and Supplementary Figure 3 and 9 where a two-tailed unpaired Student’s t 
test was used. P-values are represented in the Figures as *= P ≤ 0.05, **= P ≤ 0.01, ***= P ≤ 0.001 and 
****= P ≤ 0.0001. Standard error of the mean is represented in error bars. 
 
Whole-mount in situ hybridization and immunochemistry 
Primers used to amplify templates for riboprobe production are presented below. All probe template 
cDNAs were amplified from stage mixed WT cDNA by PCR and all PCR products, except for pkd1a, 
were subsequently cloned into pCS2+ plasmid (Turner and Weintraub, 1994). In situ hybridization was 
performed essentially as described in (Habeck et al., 2002; Thisse et al., 1993), with NBT/BCIP staining 
solution (Roche).  Expression analysis and plasmid probes for flt4, dab2, couptfII, ephrinb2a, vegfc 
probes has been previously described in (Aranguren et al., 2011; Hogan et al., 2009; Lawson et al., 	  
2001; Song et al., 2004; Thompson et al., 1998). Antibodies and primers used in this study are reported 
below. 
 
Primers and antibody 
The antibodies used in this study are: ENDOMUCIN (sc-53941, Santa Cruz Biotechnology, 1/200), 
NRP2 (AF567, R&D systems, 1/200), PROX1 (AF2727, R&D systems, 1/200), PROX1 ( 11-002, 
Angobio Co, 1/200), GOLPH-4 ( ab28049, Abcam, 1/200), LYVE1 (Ab14917, Abcam, 1/200), LYVE1 
(Ab14917, Abcam, 1/200), β-CATENIN (C2206, Sigma, 1/200), VE-CADHERIN (sc-6458, Santa Cruz 
Biotechnology, 1/200),  Alexa fluor 647 ( A21247, Invitrogen, 1/200), Alexa fluor 546 (A11010, 
Invitrogen, 1/200), Alexa Fluor 488 (A11055, Invitrogen, 1/200), Acetylated-tubulin (T7451, Sigma, 
1/500). Primers used in this study are presented in Table 1.  
 
Quantitative real time PCR analysis 
Cell isolation, RNA extraction and cDNA synthesis: Zebrafish at 3 dpf and 5 dpf were deyolked by 
pipetting with 200 ul pipette tip and rinsed in Calcium free ringers solution.  Embryos were dissociated 
via treatment with 0.25% trypsin in PBS for early time points or a 1/35 dilution of liberase Tm (Roche) 
PBS at 28°C with repeated pipetting. For the venous/lymphatic comparisons RNA was extracted from 
FACS sorted samples from 3 and 5 dpf Tg(kdrl:GFP/lyve1:DsRed2) zebrafish, with the DsRed/GFP 
positive cells corresponding to the venous cell population and the DsRed positive and GFP negative 
population corresponding to the lymphatic cell population.  FACS analysis was performed at the 
Queensland Brain Institute (University of Queensland) using a Cytopeia Influx Cell Sorter (Cytopeia, 
Seattle USA).  RNA extraction and genomic DNA removal was performed using a QIAGEN RNeasy 
micro kit (Qiagen Inc., Chatsworth, CA, USA) as per manufacturers recommendations.  RNA was 
quantified using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) 
and the integrity confirmed using an Agilent bioanalyser. RNA was amplified using the Agilent low input 
Quick Amp Labelling kit. For cDNA synthesis, residual genomic DNA was removed using the genomic 
DNA wipeout buffer included in the Quantitect reverse transcription kit (Qiagen Inc., Chatsworth, CA, 
USA). 30-50 ng of amplified mRNA was reverse transcribed into cDNA for 30 min at 42°C using a 
Quantitect reverse transcription kit (Qiagen Inc., Chatsworth, CA, USA) as per manufacturer's 	  
recommendations. Specificity of the qPCR reactions was assessed in the absence of reverse 
transcriptase enzyme by including a no-transcript control (NTC). 
Quantitative PCR:  qPCR was performed using an Applied Biosystems Viia 7 384 well qPCR machine, 
Applied Biosystems). Each qPCR reaction mixture contained 7.5 µl 2 x ABI SYBR green master mix 
(Applied Biosystems), 5ul cDNA (80-fold dilution), and 500 nM each primer to a final volume of 15 µl. 
Amplification was performed in duplicate in 384 well plates (Applied Biosystems) with the following 
thermal cycling conditions: initial UDG treatment 50°C for 10 minutes, followed by 40 cycles of 15 s at 
95°C, 60 s at 60°C. Control reactions included a no template control (NTC) and a no reverse 
transcriptase control (-RT). Dissociation analysis of the PCR products was performed by running a 
gradient from 60 to 95°C to confirm the presence of a single PCR product. The efficiency of PCR 
amplification was determined using LinReg PCR (Ruijter et al., 2009). The stability of several reference 
genes was analysed including hprt1, ef1a, rps29, rpl13 and β-actin.  Reference gene stability was 
determined using GeNorm (Vandesompele et al., 2002).  The geometric average of rps29, rpl13 and 
ef1a was used for normalisation of gene expression, except in Figure 2F where rpl13 was used, these 
genes being validated as the most stable across the sample population. 
 
Primer design: Primers were designed using Primer blast (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/) to have Tm of 60°C and to cross an exon-exon junction to avoid amplification of genomic DNA, 
whenever possible. Primers were used at a final concentration of 500 nM. 
 
Human lymphatic endothelial cells 
Human LECs were isolated and cultured as described (Norrmen et al., 2010). All experiments were 
performed with confluent  cells. 
 
PKD1 knockdown in human LECs 
siRNA transfection 
Human LECs were transfected with 50 nM of control siRNA (Qiagen, AllStars Negative Control siRNA) 
or PKD1 siRNA (ThermoScientific, SmartPool containg 4 different siRNAs) using Lipofectamine 
RNAiMAX (Invitrogen).  	   
  shRNA transduction 
Lentiviral particles were prepared using PLKO.1 lentivector (Sigma) either empty as a control or carrying 
shRNA against PKD1. Two different constructs were used, shPKD1_a 
(TTGTAGACACAGAACTCCTCG) (Sigma, TRCN0000062320) and shPKD1_b 
(AATGTCTTGCCAAAGACGGAC) (Sigma, TRCN0000062322). shRNA sequences do not overlap with 
siRNAs used in the transfection experiments. Lentiviral particles were quantified using p24 Elisa kit 
(Gentaur) according to manufacturer’s instructions. Human LECs were transduced with a multiplicity of 
infection of 10. Three days post-transduction, cells were selected for two days  in 300 ng/ml puromycin.  
 
PKD1 knockdown validation 
Total RNA was isolated using Qiagen RNeasy Plus Mini Kit (Qiagen)  24h post-transfection or 3 days 
post-transduction. Reverse transcription was performed using Transcriptor First Strand cDNA Synthesis 
Kit (Roche Diagnostics). Real-time qPCR analyses were performed on StepOnePlus (Applied 
Biosystems) using SYBR Green PCR Master Mix (Applied Biosystems). Sequences of PCR primers are 
included in table 1. Analysis of PKD1 expression relative to 18s was carried out using the comparative 
Ct (ΔΔCt) method as described by the manufacturer. 
 
Lymphatic endothelial cell spheroid sprouting assay 
800 LECs were seeded in round-bottom 96-well plates as described previously (Korff et al., 1999). The 
spheroids were collected and embedded in fibrin gels (2.5 mg/ml fibrinogen, 0.625 U/ml thrombin and 
0.15 U/ml aprotinin), treated with 100 ng/ml BSA (Sigma) or ΔNΔC-VEGFC (kindly provided by Dr. M. 
Jeltsch and Dr. K. Alitalo) for 48 h. The spheroids were fixed in 4% PFA for 1 h at RT. Nuclei were 
stained with bis-Benzimide (Sigma) and F-actin cytoskeleton with Alexa 488-conjugated phalloidin 
(Molecular Probes). Spheroids (8 per condition) were imaged using Zeiss LSM 510 META scanning 
confocal microscope. The confocal images were processed using Bitplane IMARIS Suite 6.3.1 and 
Photoshop softwares. The number of sprouts, the cumulated length of sprouts, the average of sprout 
length and the density of nuclei composing the sprouts were measured for each spheroid using ImageJ 	  
software. A two-tailed unpaired Student’s t test was used to analyze the statistical significance of the 
difference between BSA- and VEGFC-treated, or Control and PKD1-knockdown groups. 
 
Cell staining procedures and image acquisition 
Cells cultured on coverlips were fixed with 4% PFA, permeabilized with 0.1% Triton X-100 and blocked 
with 5% donkey serum. We used Alexa 488-conjugated phalloidin (Molecular Probes), rabbit anti-human 
β-CATENIN (Upstate), goat anti-mouse VE-CADHERIN (R&D systems) and rabbit anti-human ZO-1 
(Invitrogen). Coverslips were mounted using Prolong Gold anti-fade reagent containing Dapi (Invitrogen). 
Cells were imaged using Zeiss LSM 510 META scanning confocal microscope. The confocal images 
were processed using Bitplane IMARIS Suite 6.3.1 and Photoshop softwares. 
 
Western blotting 
Cells were lysed in a modified RIPA buffer, containing 50 mM Tris- HCl pH7.4, 0.25 mM Na-
deoxycholate, 150 mM NaCl, 2 mM EGTA, 0.1 mM Na3VO4, 10 mM NaF, 1 mM PMSF, 1% Triton-X 100 
and a complete protease inhibitor mixture (Roche). Protein concentration was measured using BCA kit 
(Pierce) and samples were resolved by SDS-PAGE, transferred onto Immobilon-P membrane (Millipore), 
and blotted with antibodies against rabbit anti-human GAPDH (Sigma), mouse anti-human β-CATENIN 
(BD transduction) and goat anti-mouse VE-CADHERIN (R&D systems). Western blots were developed 
using the ECL method (SuperSignal West Femto Maximum Sensitivity Substrate; Thermo Fisher 
Scientific). 
 
Calcium drug treatment 
Zebrafish embyos were exposed to DMSO, Nifedipine and Bayk8644 (Tocris Bioscience ref 1075 and 
1544 respectively) at the concentration indicated in E3 media, from 24 hpf to 4 dpf. The treatment media 
was changed twice a day.  Nifedipine and Bayk8644 were stored according to manufacturer 
recommendations.  	  
  
SUPPLEMENTAL MOVIE LEGENDS 
 
 
Supplemental Movie S1. Related to Figure 1.  
Time-lapse visualization of PL (arrow) migration between 62 hpf and 92 hpf in the trunk of a WT embryo 
in Tg(fli1a:EGFP; flt1:tomato). The video was acquired using a 10x objective, one frame every 20 
minutes.  
 
Supplemental Movie S2. Related to Figure 1. 
Time-lapse visualization of PL (arrow) migration between 62hpf and 92hpf in the trunk of a lyc1 embryo 
in Tg(fli1a:EGFP; flt1:tomato). The video was acquired using a 10x objective, one frame every 20 
minutes.  
 
Supplemental Movie S3. Related to Figure 1.  
Spinning disk visualization of a parachordal lymphangioblast between 56 and 64 hpf in the trunk of a 
control (WT/MO-pkd1b) embryo (5ng MO), which develop wildtype lymphatics. The video was acquired 
using a 40x dry objective, one frame every 4 minutes.  
 
Supplemental Movie S4. Related to Figure 1. 
Spinning disk visualization of a parachordal lymphangioblast between 56 and 64 hpf in the trunk of a 
lyc1/MO-pkd1b embryo (5ng MO). The video was acquired using a 40x dry objective, one frame every 4 
minutes.  
 
Supplemental Movie S5. Related to Figure S7. 
Analysis of co-localisation of tdTOMATO with PROX1 and NRP2 during validation of the Sox18:GFP-
Cre-ERT2 using the Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J reporter strain.  Computational masking of the 
area spanned by NRP2 expression using Imaris software allows for removal of the majority of blood 
vascular tdTOMATO.  This identifies high activity of Sox18:GCE in LECs, allowing for counting of 
individual PROX1/tdTOMATO co-expressing LEC nuclei (CAG-tdTOMATO localizes strongly to nuclei) 
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Supplemental Figure S1: Further phenotypic analysis of lyc1. Related to Figure 1 
(A-B) Representative overall morphology of WT and lyc1 mutant embryonic hearts and pericardial 
cavities at 3 (A) and 5 dpf (B). Double-sided arrows indicate the distance between the pericardium and 
heart. Dashed line indicates the outline of the myocardium. 
(C) In situ hybridization analysis of flt4 (n=22), dab2 (n=16), coup-TFII (n=20), ephrinb2a (n=17) and 
vegf-c (n=28) in lyc1 mutant embryos revealed no alterations in normal expression patterns. N values 
indicate the total number of embryos examined from an incross of known heterozygotes (expected 25% 
lyc1 mutants). Individual genotype confirmed mutant embryos are shown in the right hand panels. (D) 
Expression of cxcr4a was unchanged at 32 hpf in control WT/MO-pkd1b (embryos show no phenotype 
after pkd1b knockdown only and internally control for MO toxicity) (n=39/40) compared with 
phenotypically mutant (based on body curvature in the presence of MO-pkd1b) lyc1/MO-pkd1b embryos 
(5ng MO) (n=16/16). Expression of cxcr4b was unchanged at 32 hpf in control (WT/MO-pkd1b) 
(n=36/38) compared with phenotypically mutant lyc1/MO-pkd1b embryos (5ng MO) (n=7/7). Expression 
of cxcl12a was unchanged at 32 hpf in control (WT/MO-pkd1b) (n=50/52) compared with phenotypically 
mutant lyc1/MO-pkd1b embryos (5ng MO) (n=14/14). Expression of cxcl12b was unchanged at 32 hpf in 
control (WT/MO-pkd1b)  (n=28/37) compared with phenotypically mutant lyc1/MO-pkd1b embryos (5ng 
MO) (n=6/7).  
(E) Expression of klf2a at 24 (n=10/10) and 32 hpf (n=9/10) is normal in WT embryos. Expression of 









































Supplemental Figure S2: Parachordal lymphangioblasts fail to directionally migrate and display 
altered cell dynamics in the lyc1 mutant. Related to Figure 1.  
(A-B) Schematic overview of the movement of the leading front of individual parachordal 
lymphangioblasts (t=10.5h) from 56 hpf (scale bar: 10 µm) in (A) WT/MO-pkd1b (5ng MO) (n=3 
embryos, n=4 leading fronts) and (B) phenotypically mutant lyc1/ MO-pkd1b (5ng MO) (n=5 embryos, 
n=5 leading fronts).  
(C-D) Quantification of (C) movement of cell front and (D) origin to endpoint of cell front distance 
migrated by parachordal lymphangioblasts (t=10.5h) from 56 hpf in in WT/MO-pkd1b (5ng MO) (n=3 
embryos, n=4 leading front) and phenotypically mutant lyc1/ MO-pkd1b (5ng MO) (n=5 embryos, n=5 
leading fronts) (µm).  
(E) Quantification of duration of individual filipodial extensions in single parachordal lymphangioblasts at 
the horizontal myoseptum by time-lapse imaging (spinning disc). WT/MO-pkd1b (n=3) and 
phenotypically mutant lyc1/MO-pkd1b embryos (n=4) (5ng MO) were examined between 56-64 hpf (1 
time unit = 4 minutes).  
(F) Quantification of the number of filipodial extensions per parachordal lymphangioblasts by time-lapse 
imaging (spinning disc) in WT/MO-pkd1b (n=3) and phenotypically mutant lyc1/MO-pkd1b embryos 





































































    



























































































































Supplemental Figure S3: The lyc1 mutant lymphatic phenotype is enhanced with MO-pkd1b 
injection and targeting calcium signaling results in a lymphatic phenotype. Related to Figure 2. 
(A) Quantitative real time PCR for kdrl, cdh5, prox1a, nfatc1, nrp2a, flt4 and lyve1 transcripts normalized 
expression at 3 dpf in sorted embryonic venous and lymphatic endothelial cells. Sorted cell populations 
display the predicted enrichment of marker genes.  
(B) Quantitative real time PCR for pkd1b transcript normalized expression against ef1a and rpl13 at 3 
dpf in WT and MO-pkd1a embryos at 24hpf. pkd1b is readily detectable in whole embryo cDNA but not 
altered by pkd1a knockdown. 
(C) Quantification of parachordal lymphangioblasts in WT (n=18), lyc1 (n=9) WT/pkd1b (5ng MO) (n=21), 
lyc1/MO-pkd1b embryos (5ng MO) (n=23) at 56hpf.  
(D-E) Quantification of thoracic duct extent in (D) WT (n=48), lyc1 (n=23), WT/MO-pkd1b (5ng MO) 
(n=24), lyc1/MO-pkd1b embryos (5 ng MO) (n=21), and (E) WT (n=50), MO-pkd2 embryos (7.5 ng 
MO)(n=136) at 4dpf.  
(F) Quantitative real time PCR for cacna1s transcript normalized expression at 30 hpf in sorted 
embryonic venous and arterial endothelial cells. Endothelial expression of this calcium channel and 
Nifedipine target is confirmed. 
(G-H) The vasculature of (G) DMSO 0.05% and (H) DMSO 0.05%/Nifedipine 25 µM treated embryos in 
Tg(fli1a:EGFP y1; kdrl:mcherry s916). The thoracic duct is markedly absent in the presence of a calcium 
signaling antagonist (Nifedipine). 
(I) Quantification of parachordal lymphangioblasts in DMSO 0.2% (n=62) and DMSO 0.2%/Nifedipine 
100µm treated embryos (n=101) at 56 hpf.  PLs are unchanged in the presence of a calcium signaling 
antagonist (Nifedipine).  
(J) Thoracic duct quantification in DMSO 0.05% (n=45) and DMSO/0.05%/Nifedipine 25 µM (n=68) at 5 
dpf. Thoracic duct reduction similar to lyc1 mutants is observed. 
(K) Quantification of thoracic duct extent in WT/MO-pkd1b/0.05% ethanol (5ng MO) (n=21), lyc1/MO-
pkd1b/0.05% ethanol (5ng MO) (n=21), MO-pkd1b/ethanol 0.05%/Bayk8644 (5ng MO) (n=28) and 
lyc1/MO-pkd1b /ethanol 0.05%/Bayk8644 (5ng MO)(n=15) embryos at 4dpf. A mildly penetrant lyc1 
carrier was used. Remarkably, a phenotypic interaction with the calcium agonist is observed only in the 
mutant animals and not in the wildtype siblings. This suggests a sensitivity of mutant cells to further 
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 Supplemental Figure S4: The lyc1 lymphatic vascular phenotype is independent of collagen 
gene expression and ECM changes. Related to Figure 2. 
(A-C) Electron-microscopy imaging of the peri-notochordal region in WT, lyc1/MO-pkd1b (5ng MO) and 
MO-pkd2 embryos (7.5 ng MO). Nt=notochord, M=muscle. 
(D) Expression of col12a1, a vascular collagen, was unchanged at 24 and 32 hpf in control (WT/MO-
pkd1b) (n=27, n=37 respectively) compared with phenotypically mutant lyc1/MO-pkd1b embryos (5ng 
MO) (n=37, n=12 respectively).  
(E) Expression of col9a2 was unchanged at 48 hpf in control (WT/MO-pkd1b) (n=10) compared with 
phenotypically mutant lyc1/MO-pkd1b embryos (5ng MO) (n=10).  
(F-G) Overall morphology of (F) MO-pkd1a/MO-pkd1b (5ng MO each) and (G) MO-pkd1a/MO-
pkd1b/MO-col2a1a morphants (5,5,1 ng MO respectively). Knockdown of Col2a1a rescues the gross 
curvature phenotype as previously described (Mangos et al., 2010). 
(H). Quantification of col9a2 expression as the anterior posterior extent of expression in the notochord, 
delineated by somites boundaries.  No increase in col9a2 extent was observed. 
(I) Quantification of thoracic duct extent in MO-pkd1a/MO-pkd1b embryos (n=21) and 
pkd1a/pkd1b/col2a1a morphants  (n=19). Despite rescue of the gross curvature phenotype, TD extent is 
not rescued. 
(J) Quantification of the number of collagen fibers in the medial layer of the peri-notochordal region in 
WT (n=3), WT/MO-pkd2 (7.5 ng MO) (n=3), WT/MO-pkd1b (5 ng MO) (n=3) and lyc1/MO-pkd1b 
embryos (5ng MO)(n=3). No change was observed in peri-notochordal collagen.  











































































































Pkd1+/+Pkd1 ECKO (Tie2:Cre) Pkd1 ECKO (Tie2:Cre) Pkd1 ECKO (Tie2:Cre)
Supplemental Figure S5: Endothelial knockout of Pkd1 does not affect blood vascular 
development and lymphatic morphological defects are observed in Pkd1KO embryos from 11.5 
dpc. Related to Figure 3.  
 (A-B) Overall morphology of lymphovenous valves in (A) WT (n=2) and (B) Pkd1KO (n=3) coronal 
sections stained with PROX1, LYVE1 and ENDOMUCIN based on previous studies (Srinivasan and 
Oliver, 2011). LS: Lymph sac; CV: Cardinal Vein. White arrow and inset indicate lymphovenous valve. 
Scale bar: 100 µm 
(C) Representative morphology of subcutaneous blood vascular network in WT (n=7), Pkd1KO (n=7), 
Pkd1iΔECKO (n=3) at 14.5 dpc, stained with ENDOMUCIN. Scale bar: 200 µm 
(D) Lateral views of the representative morphology of the blood vascular network in whole mount WT 
(n=5) and Pkd1KO  (n=5) embryos at 11.5 dpc, stained with ENDOMUCIN. Scale bar: 100 µm 
(E) Quantification of the width of subcutaneous vessels (µm) across the whole skin in WT (n=6), and 
Pkd1iΔECKO   (n=3) embryos (n=2398, n=1200 measurements respectively. Two areas of 2000*900 µm 
centered on the midline were used for quantification in every embryo). 
(F) Quantification of the number of branch points per area in WT (n=6) and Pkd1iΔECKO (n=3) embryos (3 
areas of 2000*500 µm centered on the midline were used for quantification in every embryo). 
(G,H) Representative lateral view of (G) WT (n=5) and (H) Pkd1KO (n=5) bisected embryos with at 10.5 
dpc stained with ENDOMUCIN and PROX1. Scale bar: 50 µm. CCV: common cardinal vein, iLECs: 
initial lymphatic endothelial cells.  
(I,J) Morphology of representative sLECs in (I) WT (n=5) and (J) Pkd1KO  (n=5) embryos stained for 
NEUROPILIN2. Scale bar: 10 µm 
(K) Quantification of the average width of leading sprouts (µm) in WT (n=5) and Pkd1KO (n=5), (n=18, 
n=27 measurements respectively, across leading lymphatic vessels, averaged) at 11.5 dpc.  
(L) Quantification of nuclei per µm of vessel in WT (n=5) and Pkd1KO (n=5) (n=39, n=66 measurements 
respectively) at 11.5dpc. 
 (M-N) Subcutaneous lymphatic vasculature in WT and Pkd1ECKO (Tie2:Cre+; Pkd1f/f) mutants at 14.5 
dpc.  
(O) Quantification of branch points/area (2000*1500 µm area on both sides of the midline) in WT (n=4 
embryos) and Pkd1ECKO (Tie2:Cre+; Pkd1f/f) (n=4 embryos) embryos at 14.5 dpc.  	  
(P) Quantification of the average width of lymphatic vessels (µm) across the whole skin in WT (n=4 
embryos) and Pkd1ECKO (Tie2:Cre+; Pkd1f/f) (n=4 embryos) embryos. The average is shown of n=800 
and n=800 measurements respectively, across leading lymphatic vessels from both side of the midline at 
14.5 dpc.  
(Q) Quantification of nuclei/100 µm length of vessel in WT (n=4 embryos) and Pkd1ECKO (Tie2:Cre+; 
Pkd1f/f) (n=4 embryos) (n=10 representative vessels were counted per embryo at the leading edge and 
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Supplemental Figure S6: Validation of gene targeting. Related to Figure 3. 
(A-C) Whole mount X-gal staining of β-gal in Tie2:Cre-/-, Rosa26R-/- and Tie2:Cre+, Rosa26R+  embryos 
shows that the Cre activity in the subcutaneous vasculature is strong in the blood vascular endothelium 
but not the lymphatic vascular endothelium at 14.5 dpc.  
(D-E) Whole mount X-gal staining of β-gal in Sox18-CREert2, Rosa26R embryos show CREert2 activity 
in 10.5 and 14.5 dpc embryos.  
(F). Whole mount X-gal staining indicates CRE activity, which is selective for endothelial cells, 
recapitulating the Sox18 expression pattern.  Note that there is no co-stain to determine vessel identity in 
this experiment. 
(G) Genotyping of Pkd1iΔECKO with primers F4/R4 (Piontek et al., 2004) shows a band indicating a 
defloxing event (subsequently confirmed by sequencing). This shows that the Pkd1 locus is inactivated 
in a proportion of cells in the endothelial specific Sox18:GCE strain (DNA from whole tissue extract).  
(H-K) Subcutaneous vessels analysed in Sox18:GFP-Cre-ERT2, Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J 
co-stained with NRP2 and PROX1 to identify the lymphatic vessels at 13.5 dpc. H. Low magnification 
image of whole skin showing tdTOMATO expression in blood and lymphatic endothelial cells. I.  PROX1 
stains only the lymphatic vessels. J. Lymphatic vessels make up a proportion of total cells expressing 
tdTOMATO (indicated by the hashed lines). K. Image processing to remove most blood vascular 
tdTOMATO (by computational masking of NRP2 positive tissue using Imaris software) reveals strong 
activity of Sox18:GFP-Cre-ERT2 in cells of the lymphatic network. Scale bar: 200 µm 
(L-O). Example of a lymphatic vessel with tdTOMATO expression as analysed by Imaris image 
processing to remove non-lymphatic endothelial staining (eg, panels M-O). Inset in N and O are 
individual co-stained nuclei (PROX1 and tdTOMATO (CAG-tdTOMATO localizes to nuclei)) allowing 
precise cell counting. Quantification of whole skin as described in Figure 3 and related text, using this 
approach revealed that n=663/1138 LECs were tdTOMATO, PROX1 and NRP2 positive (58.2%).  
(P-Q) Alternative masking in Imaris using PROX1 expression as the mask identified the same co-
localisation as using an NRP2 mask (inset are individual nuclei). Scale bar: 10 µm 
(R-S) Sox18:GFP-Cre-ERT2, Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J co-stained with LYVE1 and PROX1 
at 11.5 dpc labels the cardinal vein from which early LECs derive. CV: Cardinal Vein, H: Heart. Scale 









































































































































































































Supplemental Figure S7: Validation of shRNA and siRNA targeting of PKD1 expression in LECs 
in vitro. Related to Figure 4. 
(A-C) Morphology of human LEC spheroids treated with control and two alternative PKD1 shRNA 
(shPkd1_a and shPkd1_b respectively) in BSA or VEGFC supplemented conditions, stained with F-
ACTIN (green) and DAPI (blue). Scale bar: 100 µm.  
(D-F) Quantification of number of sprouts (D), total sprout length (mm) (E) and number of nuclei per 100 
µm of sprouts (F) in spheroids treated with control or PKD1 targeting shRNA (shPkd1_a and shPkd1_b 
respectively) in BSA or VEGFC supplemented conditions.  
(G-H) Quantification of PKD1 mRNA expression level relative to 18s in human LEC spheroids treated 
with control and two alternative PKD1 shRNA (shPkd1_a and shPkd1_b respectively) (G) and with 
control and PKD1 targeting siRNA (H) in VEGFC supplemented conditions.  
(I) Western-blot quantification of β-CATENIN, VE-CADHERIN and GAPDH protein levels in cultured 
human LECs treated with control and PKD1 targeting siRNA.  
(J) Quantification of total sprout length (mm) in spheroid treated with control or PKD1 targeting siRNA in 
BSA or VEGFC supplemented conditions.  








































































































Supplemental Figure S8: No evidence for a contribution of primary cilia to lymphangiogenesis. 
Related to Discussion section.   
(A-B) The vasculature Tg(lyve1:DsRed2)nz101 in (A) wild-type sibling  and (B) ift88tz288 mutant embryos at 
56 hpf (arrowheads indicate parachordal lymphangioblasts and white arrows indicate venous sprouts).  
(C-D) Overall morphology of (C) wild-type siblings and (D) ift88tz288 mutants at 5 dpf. (E-H) The 
vasculature Tg(lyve1:DsRed2nz101; flt1:YFPhu4624Tg) of (E,G) WT and (F,H) ift88tz288 mutants at 5 dpf.  
(I-J) Quantification of (I) secondary sprouts in WT (n=12) and ift88tz288 (n=10) at 56 hpf and (J) thoracic 
duct extent in WT (n=16) and ift88tz288 (n=18).  
(K-N) Overview of primary cilia localization in the trunk of (K,M) WT (n=4) and (L,N) lyc1 mutants (n=3) 
embryos at 30 hpf, stained for blood vessels (Kdrl-Cherry), nuclei (DAPI) and primary cilia (Acetylated-
tubulin) markers. Arrowheads indicate example of discrete primary cilia.  
(O) An individual representative primary cilium in a lyc1 embryo.  
(P) Transient expression of a Pkd1-YFP BAC construct in an arterial intersegmental vessel and adjacent 
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Table 1 Primers used in this study
Name Use Sequence direction Sequence
marker 1 - 54.65Mb polymorphic marker used for positional cloning F 5’-GACTACACCGGTTGTGTCTG-3’
R 5’-GTCCCTTCAGATCGGTCAC-3’
marker 2 - 54.73Mb polymorphic marker used for positional cloning F 5’-ACCACACAGACAAACTCTGG-3’
R 5’-CGTCACATGTTGATCACAGAC-3’
marker 3 - 54.77Mb polymorphic marker used for positional cloning F 5’-CAGAGGCTTCTCCTATCACAC-3’
R 5’-TGACAACCATGCTTTGAGTC-3’
marker 4 -  54.92Mb polymorphic marker used for positional cloning F 5’-TGAACAAATGGTCGCATGTT-3’
R 5’-ACTTTTCCATCTGCTGCTCC-3’
lyc1 mutation site sequencing lyc1 mutation (R3607X) F 5’-TTGCTATTCCTGTGTGTTCTG-3’
R 5’-ACATCAACCGTCTGACATC-3’
lyc1 mutation site Introduction of an Hinp1I restriction fragment Hinp1I-R 5’CGCACTCGGGGGATCCGCTGGACCACGC-3'
 length polymorphism by PCR for rapid genotyping
of lyc1 fish.  The presence of the lyc1 stop codon 
mutation in the pkd1a sequence removes 
the induced Hinp1I restriction cutting site.
pkd1a riboprobe riboprobe amplification with T3 polymerase Tag F 5'-ACGTGTGTGTGTCTCTGGAC-3'
R 5'GGATCCATTAACCCTCACTAAAGGGAACTGTACTCTGGGTATTGTGTGC-3'
cxcl12a cloning subcloning riboprobe in PCS2+ vector F 5'-GCGCGAATTCAAAAAGCCCAACAGCAGCAGG-3'
[restriction sites in bold] R 5'-GCGCCTCGAGACACGGAGCAAACAGGACTCC-3'
cxcl12b cloning subcloning riboprobe in PCS2+ vector F 5'-GCGCGAATTCTATTGCCCAGCAATGTTCGC-3'
[restriction sites in bold] R 5'-GCGCCTCGAGTGTGACCAGAGGGCTAGTGT-3'
cxcr4a cloning subcloning riboprobe in PCS2+ vector F 5'-GCGCGAATTCTGCTCACTCTGCCATTCTGG-3'
[restriction sites in bold] R 5'-GCGCCTCGAGACAGCAGTGAAAGTACGCGA-3'
cxcr4b cloning subcloning riboprobe in PCS2+ vector F 5'-GCGCGAATTCTCGCAGACCTCCTGTTTGTC-3'
[restriction sites in bold] R 5'-GCGCCTCGAGGCAGTGGAAATATGCCAGCG-3'
col9a2 cloning subcloning riboprobe in PCS2+ vector F 5'-GCGCGAATTCTTTCAGTGTCCAACCAACTG-3'
[restriction sites in bold] R 5'-GCGCCTCGAGGATCCTTGCATTCCCATC-3'
col12a1 cloning subcloning riboprobe in PCS2+ vector F 5'-GCGCGAATTCTCTGTATGCTGATGGAGAGG-3' 
[restriction sites in bold] R 5'-GCGCCTCGAGGCATCATACTGAGCGTAAACC-3'
Cre coding sequence gentoyping for the presence of Cre F 5'-CGAACGCACTGATTTCGACC-3'
R 5'-AACCAGCGTTTTCGTTCTGC-3'
Cre coding sequence 
(alternative) gentoyping for the presence of Cre F 5'-GTTTCACTGGTTATGCGGCG-3'
R 5'-GGTGCTAACCAGCGTTTTCG-3'
LacZ coding sequence genotyping for the precesence of LacZ F 5'-GGCGGCTTCGTCTGGGACTG-3'
R 5'-CAGGCGGCAGTAAGGCGGTC-3'
18S shRNA qPCR quantification of 18S expression F 5'-AGGAATTCCCAGTAAGTGCG-3'
R 5'-GCCTCACTAAACCATCCAA-3'
pkd1 shRNA qPCR quantification of PKD1 expression F 5'-CTTCCGGTGGACCATCAACG-3'
